# ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech with a 59.42% Potential Upside

- Link: https://www.directorstalkinterviews.com/adma-biologics-inc-adma-stock-analysis-a-biotech-with-a-59-42-potential-upside/4121241194
- Published: 2026-02-23T11:32:39+00:00
- Author: Madison Wilson

ADMA Biologics Inc (NASDAQ: ADMA) presents a compelling opportunity for investors
seeking exposure to the biotechnology sector, specifically within the realm of plasma-
derived biologics. With a market capitalization of $3.84 billion, ADMA is steadily
paving its path in the healthcare industry, focusing on critical treatments for 
immune deficiencies and infectious diseases.

The company, headquartered in Ramsey, New Jersey, is renowned for its flagship products
such as BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies addressing
primary humoral immunodeficiency. Additionally, ADMA offers Nabi-HB, a treatment
for acute exposure to Hepatitis B, and maintains a forward-looking pipeline of plasma-
derived therapeutics.

Currently trading at $16.1, ADMA’s stock has experienced minor fluctuations, with
a 52-week range of $13.99 to $24.51. Despite a slight price drop of -0.22 (-0.01%)
recently, the stock’s technical indicators suggest resilience, with the 50-day and
200-day moving averages at $17.80 and $17.57, respectively. The Relative Strength
Index (RSI) of 67.30 indicates that the stock is approaching overbought territory,
warranting close monitoring by investors.

A notable highlight for ADMA is its projected forward P/E ratio of 17.13, which 
suggests favorable earnings expectations, although trailing P/E and PEG ratios are
currently unavailable. The company’s robust revenue growth of 12.00% and an impressive
Return on Equity (ROE) of 63.17% reflect its operational efficiency and profitability
potential.

Analyst sentiment towards ADMA is overwhelmingly positive, with three buy ratings
and no hold or sell recommendations. The target price range spans from $17.00 to
$30.00, with an average target of $25.67, indicating a substantial potential upside
of 59.42% from the current trading price. This optimistic outlook is underpinned
by ADMA’s strategic expansion in plasma collection and its innovative product offerings.

Investors should note that ADMA does not currently offer a dividend yield, and its
payout ratio is at 0.00%, channeling more resources into growth and development.
The company’s free cash flow stands at $2,958,500.00, providing a solid foundation
for continued investment in its core and pipeline products.

For investors keen on the biotechnology sector, particularly those interested in
niche markets like plasma-derived biologics, ADMA Biologics presents a promising
prospect. The company’s strategic positioning, strong analyst endorsements, and 
significant potential upside make it a stock worth watching closely. As ADMA continues
to innovate and expand its market footprint, it remains a noteworthy contender in
the healthcare landscape.

Share on: